The high expression level of MIDN was correlated with unfavorable overall survival (OS) in patients with LGG and acute myeloid leukemia (LAML), with poor disease-specific survival (DSS) in patients of LGG and LUSC, and with a shortened progression-free interval (PFI) in LUSC patients (Figure 2B–D). Here, MIDN is linked to acute myeloid leukemia.